Fondaparinux Market Report 2026

Fondaparinux Market Overview

• Fondaparinux market size has reached to $1.98 billion in 2025 • Expected to grow to $2.81 billion in 2030 at a compound annual growth rate (CAGR) of 7.2% • Growth Driver: The Increasing Prevalence Of Thromboembolic Conditions Driving Growth Of The Market Due To Rising Health Risks In Aging Populations • Market Trend: Addressing Unmet Needs In Pediatric Venous Thromboembolism Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Fondaparinux Market?

Fondaparinux is a synthetic anticoagulant that works by selectively inhibiting Factor Xa, preventing the formation of blood clots. It is commonly used to reduce the risk of thromboembolic events in patients at risk. The main uses of fondaparinux are for treating deep vein thrombosis (DVT) and pulmonary embolism. Deep vein thrombosis (DVT) is a medical condition where a blood clot forms in a deep vein, usually in the legs, potentially leading to serious complications if untreated. This is administered through various routes, such as oral, parenteral, and other methods. It is available in different dosage forms, including injections and pre-filled syringes. The drug is distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies. Key end users include hospitals, specialty clinics, and other healthcare providers.

What Is The Fondaparinux Market Growth Forecast?

The fondaparinux market size is expected to see strong growth in the next few years. It will grow to $2.81 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to aging population with clotting risks, increase in cardiovascular surgeries, demand for predictable anticoagulation therapy, expansion of outpatient anticoagulant use, preference for low monitoring drugs. Major trends in the forecast period include increasing use in thromboembolism prevention, growing adoption in post-surgical care, rising preference for factor xa inhibitors, expansion of pre-filled syringe formulations, higher utilization in hospital-based anticoagulation.

Global Fondaparinux Market Segmentation

1) By Type: Deep Vein Thrombosis, Pulmonary Embolism 2) By Route of Administration: Oral, Parenteral, Other Routes of Administration 3) By Dosage Form: Injection, Pre-filled Syringe 4) By Distribution Channel : Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 5) By End Users: Hospitals, Specialty clinics, Other End Users Subsegments: 1) By Deep Vein Thrombosis: Prophylaxis (Prevention), Treatment (Management) 2) By Pulmonary Embolism: Acute Pulmonary Embolism, Chronic Pulmonary Embolism Management

What Are The Drivers Of The Fondaparinux Market?

Increasing prevalence of thromboembolic conditions is expected to propel the growth of the fondaparinux market. Thromboembolic conditions are health problems caused by blood clots that form in blood vessels and can block blood flow to important parts of the body. The rising prevalence of thromboembolic conditions can be attributed to the increasing aging population, as older individuals are more prone to conditions such as deep vein thrombosis and pulmonary embolism due to slower blood circulation and other health issues. Fondaparinux is used to help prevent and treat thromboembolic conditions by stopping the formation of harmful blood clots in the body. For instance, in January 2025, according to the Centers for Disease Control and Prevention, a US-based government agency, approximately 60,000 to 100,000 fatalities occur annually in the United States due to venous thromboembolism (VTE), with a significant number of individuals experiencing long-term complications from the condition. Therefore, the increasing prevalence of thromboembolic conditions will drive the growth of the fondaparinux industry. The rising healthcare expenditures are expected to propel the growth of the fondaparinux market. Healthcare expenditures refer to the total amount of money spent on medical services, treatments, and healthcare-related products by individuals, governments, and organizations. Increasing healthcare expenditures are driven by the rising demand for advanced medical treatments and technologies, as well as the growing prevalence of chronic diseases and an aging population that requires more healthcare services. Healthcare expenditures increase with the use of fondaparinux as its demand rises for treating cardiovascular and thromboembolic conditions, contributing to higher medical costs. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure grew by 5.6% in nominal terms from 2022 to 2023, showing a notable acceleration compared to the 0.9% increase seen in 2022. Therefore, rising healthcare expenditures will drive the growth of the fondaparinux industry.

Key Players In The Global Fondaparinux Market

Major companies operating in the fondaparinux market are Sanofi S.A., Viatris Inc., Mylan N.V., Sandoz Group AG, Zydus Lifesciences Limited, Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Limited, Sun Pharmaceutical Industries Limited, Lupin Pharmaceuticals Inc., Cipla Limited, Aspen Pharmacare Holdings Limited, Jiangsu Hengrui Pharmaceuticals Co. Ltd., Sihuan Pharmaceutical Holdings Group Ltd., Apino Pharma Co. Ltd., Home Sunshine Pharma Co. Ltd., Zhejiang Borui Pharmaceutical Co. Ltd., Alchemia Limited, Amphastar Pharmaceuticals Inc., Hikma Pharmaceuticals plc, Fresenius Kabi AG

Global Fondaparinux Market Trends and Insights

Major companies operating in the fondaparinux market are focusing on product innovation such as pediatric-focused drug development to expand the therapeutic applications of fondaparinux, address unmet medical needs, and improve treatment options for younger patients suffering from conditions such as venous thromboembolism (VTE). Pediatric-focused drug development is the process of creating and adapting medications specifically for safe and effective use in children, taking into account their unique physiological and developmental needs. For instance, in December 2024, Mylan N.V., a US-based pharmaceutical company, has obtained Food and Drug Administration (FDA) approval for Arixtra in the treatment of venous thromboembolism (VTE) in pediatric patients aged 1 year and older, weighing a minimum of 10 kg. Additionally, Arixtra is approved for adult indications, including the prophylaxis of deep vein thrombosis (DVT) and the treatment of both acute DVT and pulmonary embolism. The pediatric approval is supported by a retrospective, open-label clinical study involving 366 patients, which showed that 44.9% of participants achieved complete resolution of at least one clot, while 44% achieved full resolution of all clots.

Regional Insights

North America was the largest region in the fondaparinux market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Fondaparinux Market?

The fondaparinux market consists of sales of active pharmaceutical ingredient, injection, and fondaparinux kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Fondaparinux Market Report 2026?

The fondaparinux market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the fondaparinux industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.